Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revolutionizing Blood Cancer Therapy: Next-Gen CAR-T Therapy with In Vivo Nanoparticle Targeting

Project description

Delivering CAR-T cell therapy through a single injection

Immunotherapy has revolutionised the treatment of haematological malignancies, but clinical application remains constrained by high costs, lengthy manufacturing processes and limited hospital capacity. A simpler, cost-effective approach that generates therapeutic immune cells directly inside the body could transform access to this life-saving treatment. The EIC-funded NANOCAR project investigates the use of engineered lipid nanoparticles to deliver CAR-encoding genetic sequences to circulating T cells. This mechanism facilitates the in vivo production of durable CAR-T cells, circumventing the requirements for ex vivo cell harvesting and viral vectors. The project aims to significantly decrease treatment costs and expand the availability of these therapies to more patients with oncological and autoimmune conditions.

Objective

CAR-T cell therapy has transformed the treatment landscape for blood cancers but remains restricted to a minority of patients due to high costs, lengthy ex vivo manufacturing, and limited specialized hospital capacity. Current therapies cost €300–350k per patient, take weeks to deliver, and suffer from bottlenecks in viral vector manufacturing. Moreover, ex vivo processing drives T-cell exhaustion and raises safety risks, while access remains out of reach for up to 70% of eligible patients.
NanoCell Therapeutics introduces NANOCAR, a first-in-class, non-viral, in vivo CAR-T platform based on proprietary T cell-targeted lipid nanoparticles (tLNPs). This system delivers minicircle DNA encoding a CAR transposon together with short-lived mRNA encoding the Sleeping Beauty transposase, enabling stable genomic integration of CAR constructs directly within circulating T cells. A single administration generates durable CAR-T cells in vivo, bypassing the need for patient cell harvesting, viral vectors, and costly GMP expansion.
The project will advance NCTX-01, our lead clinical candidate, towards first-in-human readiness by: (i) establishing GMP-ready manufacturing of all components, (ii) developing a robust analytical and stability package, (iii) demonstrating safety and efficacy in relevant preclinical models, and (iv) aligning with regulatory authorities. Parallel business objectives include IP strengthening, investor-ready business planning, and preparation for licensing discussions with major pharmaceutical partners.
By achieving TRL 5, NANOCAR will validate a transformative, scalable, and cost-efficient alternative to conventional CAR-T. This innovation has the potential to expand patient access to life-saving therapies, cut treatment costs by up to 99%, and extend beyond oncology into autoimmune diseases and solid tumors. Success will position Europe at the forefront of next-generation cell and gene therapy, driving both health and economic impact.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2025-TRANSITIONOPEN

See all projects funded under this call

Coordinator

NANOCELL THERAPEUTICS B.V.
Net EU contribution
€ 2 311 463,75
Address
PADUALAAN 8
3584 CH UTRECHT
Netherlands
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
No data